SUDA Pharmaceuticals Limited announced that it has finalised the Product Development, Licence and Supply Agreement (Agreement) with Cann Pharmaceutical Australia Ltd. (CPA). SUDA signed a binding term sheet with CPA. The Agreement is to develop a novel oral spray of pharmaceutical-grade cannabinoid derivatives for the treatment of: drug resistant epilepsy, melanoma and motion sickness throughout the world. Following completion of the feasibility study, which is fully funded by CPA, further product development costs are to be determined by SUDA and CPA jointly and will be fully funded by CPA. On regulatory approval, SUDA will arrange the manufacture and supply of the product to CPA with a 10% handling fee.